Connecting Investors and Real World Businesses in the Cannabis Space
David Traylor and Matt Daugherty from Golden Eagle Partners welcome attendees. Golden Eagle Partners is a trusted advisor to global cannabis and psychopharmacology companies with a focus on closing strategic and financing transactions that match the near and long-term goals of its clients. Golden Eagle Partners specializes in finding the right transaction to help its clients thrive – mergers, acquisitions, reverse mergers, equity and debt financings, and incremental transactions such as licensing, joint ventures, and co-development arrangements.
David Traylor
Matt Daugherty
As the global cannabis industry continues to emerge, there have been some recent hiccups in the road inetrnationally with valuations falling in North America and other challenges abroad. This discussion will address some of the ups and downs we’ve seen in the cannabis markets around the world, including THC+ and THC- products.
David Traylor
Steve Winokur
Jamie Pearson
Robert T. Hoban
Lisa Haag
Peter Homberg
Kai-Friedrich Niermann
Cornelius Maurer
Germany is the largest cannabis market to date. The country not only operates a reimbursement scheme for cannabinoid-based medicines, but also has a flourishing industrial hemp/CBD market. Now, the German government intends to regulate adult use cannabis. How did the market evolve to date and what will the reality of the future of German cannabis markets look like?
Matt Daugherty
Dr. Constantin von der Groeben
Benedikt Sons
Daniel Haymann
The European Union is a trade union with no borders. Nevertheless, cannabis regulation is a very domestic topic and markets still face different rules and regulations depending on their national regulatory framework. How will the situation look like in a mid-term perspective? How many member states will have regulations for adult use cannabis? How far will harmonization of joint market organization have developed?
David Traylor
Peter Glik
Rob McEvoy
Lewis Koski
Hilary Black
North American cannabis markets are the most developed on a global level. Canada has established regulations for hemp, medicinal cannabis and adult-use markets. The U.S. are still waiting on federal legalization, but there exists a lot of experience on a state level. This panel gives significant insight into what other emerging markets can learn from the success and failures of North American markets.
David Engel
Dr. rer. nat. Adrian Fischer
Vera Broder
Different nations across Europe allow for the cultivation, manufacturing and processing of medical cannabis. Few of the facilities are really in operation, fully EU-GMP compliant and able to delver what was promised. Europe’s markets are competing and not collaborating. Few real sales markets other than Germany are established. Some countries like the Czech Republic, France or Poland show tendencies with a rising number of prescriptions and new regulations for patient access. The German market itself is oversaturated and has many regulatory hurdles to consider. All in all, investors should understand the complexity of market dynamics, especially in regard to timeline and planning of such complex ventures.
Matt Daugherty
Joel Redelman
Giadha A. DeCarcer
Todd Boren
International cannabis markets are still emerging. Some of these markets are more mature than others. International markets are far from harmonization. All of them are restricted by the massive trade barrier of the 61. single convention on the control of narcotic substances. Where are we today and how can strategic investment help to enable a global cannabis industry?
Alex Revich
Philip Schetter
Carmen Doran
Luc Richner
An old saying claims: “during a gold rush, sell the shovels.” The green gold rush is a once-in-a-lifetime opportunity that arises today. Many entrepreneurs and investors have started in the industry and fist results of over-supply and diminishing opportunity can already be observed. Vertical integration is a buzz-word in our industry, but is it the way to go or should ventures focus on specific core competencies and on secondary supply chains? Because after all, with millions of miners looking to seize the opportunity, you should consider to invest in those who sell the picks and shovels.
To truly understand the future of cannabis, it’s important to approach it from different angles and challenge existing perceptions and stigmas. This presentation will offer a fresh perspective on the cannabis industry, exploring its potential from a variety of viewpoints and shedding light on untapped opportunities. By breaking down barriers and opening our minds to new ideas, we can pave the way for a more innovative, inclusive, and successful cannabis industry.
Lisa Haag
David Traylor
Giovanni Venturini Del Greco
Dr. Sebastian Vaughan
Research and development (R&D) in the pharmaceutical industry’s cannabis sector spans a wide range of areas, including plant genetics, novel delivery systems, and the development of plant-based and finished medicines. Despite years of prohibitionist policies causing a research backlog, international drug control regimes now explicitly allow research into cannabis under strict safety and security protocols. As the cannabis industry continues to evolve, R&D is desperately needed to develop innovative products and stay competitive. This panel will explore investment opportunities in R&D to bring cutting-edge cannabis products to market and pave the way for the industry’s future success.
Globally, consumers spent nearly $40 billion USD on legal THC products in 2022, with Americans accounting for 96% of sales. This encouraging data projects sales to soar to over $76 billion by 2027. While the U.S. Cannabis market has grown to one-third the size of the country’s beer sales, Germany’s plans for cannabis legislation open doors to countless opportunities across Europe and across the map. Industry leaders know the “when” and “why” of Germany’s two-phased cannabis program release, but few have yet to tackle how investors can capitalize throughout the legalization process. With positive ripple effects expected within the European market, all eyes are on Germany’s program. This session will examine both the potential investment strategies and challenges ahead for Germany, what that may mean for the rest of Europe, and how investors and potential operators can position themselves for long-term growth and success in a burgeoning, global adult-use market.
Nic Easley
David Traylor
Oliver Lamb
Trenton Birch
Bernhard Babel
Bret Worley
The global cannabis industry is still emerging. The commodity cannabis, is becoming more and more relevant for conventional industries, from food and health care via fashion to luxury niche segments. With adult use reform coming across several nations, the opportunity for other industries in those countries has been unlocked. The biggest question today is: where are global cannabis sectors going and where will the best investments be?
Find us
